TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02247102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Description: Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isomaltulose
Description: Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg).
Study: NCT01027325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Starch digestibility and carbohydrate quantity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Starch digestibility and carbohydrate quantity
Study: NCT04356989

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: The adminstration dose is decided by the attending physician in advance based on the patients' CrCl and in compliance with local market authorization of rivaroxaban.
Study: NCT03738072

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: StiMiC stimulation condition
Description: This new condition of stimulation of electrical Brain Stimulation will be evaluate to determine if this stimulation is more efficient that standard stimulation condition
Study: NCT01057511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crinone 8%
Description: Crinone 8%, 90mg / p.v. / Qd, 7 days totally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone 20mg/ i.m./ Qd, 7 days totally.
Study: NCT01959633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib 960 mg b.i.d. for each course of treatment lasting 28 days
Study: NCT00244101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NCPAP Group
Description: Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
Study: NCT01959633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon
Description: In the Phase I are included 3 cohorts. Cohort 1) Peg-interferon 1 µg/Kg one time per week s.c. Cohort 2) Peg-interferon 2 µg/Kg one time per week s.c. Cohort 3) Peg-interferon 3 µg/Kg one time per week s.c. Interferon treatment should start after 15 days of Vemurafenib only~In the Phase II is included the cohort selected by phase I due to MTD and expanded at RD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib 60 mg o.d. (21 days on followed by 7 days off)
Study: NCT03348332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise pregnant women
Description: A supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 10 to 39) was conducted. Each session consisted of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training. Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor during the training sessions to control the intensity.
Study: NCT04968613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar monotherapy
Description: In addition to basic treatment, the patient also received Madopar treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: senfrol monotherapy
Description: In addition to the basic treatment, the patient also received the rofosson treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo monotherapy
Description: In addition to basic treatment, the patient also received selegiline treatment
Study: NCT03354598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem-Etzadroxil/Probenecid
Description: Treatment of uncomplicated urinary tract infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Treatment of uncomplicated urinary tract infection
Study: NCT01204567

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: Group-based Aerobic Interval Training twice a week in 12 weeks, based on the Ulleval model. The Norwegian Ulleval Model is a group-based aerobic interval training program which is widely used in Scandinavian hospitals for patients with coronary disease. It is designed to improve physical capacity, body awareness and emotional well-being.
Study: NCT01524120

Intervention type: DEVICE
Intervention: Endomicroscopy (iCLE, Pentax, Tokyo, Japan)
Description: Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
Study: NCT03855982

Intervention type: DRUG
Intervention: Drug inducing myocarditis
Description: Drugs susceptible to induce myocarditis
Study: NCT00244101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISX Group
Description: Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
Study: NCT05727982

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samples, Biological samples analysis, Cardiology visit.
Description: These interventions are important to study all patients recruited

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samples, Biological samples analysis, Cardiology visit.
Description: These interventions are important to study all patients recruited

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samples, Biological samples analysis, Cardiology visit.
Description: These interventions are important to study all patients recruited
Study: NCT03161080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neovis Total Multi® Eye Drops
Description: Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vismed Multi® Eye Drops
Description: Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrabak® Eye Drops
Description: Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
Study: NCT02247102

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg).
Study: NCT04545645

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: median nerve mobilization
Description: The patient is placed in a supine position and his cervical spine with 25º of lateral flexion on the opposite side of the member in which we perform the test. First a passive scapular depression is performed, 90º of shoulder abduction combining external shoulder rotation. Next, a supination of the forearm is performed with wrist extension and finger extension. Finally, the elbow is extended to the limit of resistance or when the investigator observes the elevation of the shoulder girdle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neural stress provocation with cognitive auditory distraction
Description: Neural provocation of the median nerve is performed but an auditory distraction is added with a metronome with a constant time of 50 beats per minute.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Providing neural stress with a motor distraction
Description: The neural provocation of the median nerve is performed and we add a motor distraction that consists of the patient intermittently squeezing a ball with the opposite hand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neural stress provocation with auditory and motor cognitive distraction.
Description: The neural provocation of the median nerve is performed, we add auditory distraction with the metronome with a constant time of 50 BPM and a motor distraction consisting of squeezing a ball to the rhythm that sounds the metronome.
Study: NCT02160262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
Study: NCT04054531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN046
Description: IV infusion
Study: NCT04139928

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium citrate or magnesium oxide
Description: Single-dose (300 mg) of magnesium citrate or magnesium oxide

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04054531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN046
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study: NCT01471548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study: NCT04560634

Intervention type: DRUG
Intervention: Norepinephrine
Description: Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes

Intervention type: DRUG
Intervention: Norepinephrine
Description: Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes

Intervention type: DEVICE
Intervention: ClearSight®, Edwards Lifescience, Irvine, CA
Description: All patients are connected to a ClearSight® monitor (ClearSight®, Edwards Lifescience, Irvine, CA) by an inflatable finger cuff placed on the midphalanx of hand middle or ring finger with no radial artery catheter and its heart reference system (HRS) is zeroed at the level of the patient's midaxillary line.~The ClearSight® monitoring is started in the pre-anaesthesia room and calibrated for 5 minutes before recording. The monitoring continues throughout the procedure until patient transfer in the recovery room. All data are anonymously collected on a USB pen for statistical analysis.

Intervention type: DEVICE
Intervention: ClearSight®, Edwards Lifescience, Irvine, CA
Description: All patients are connected to a ClearSight® monitor (ClearSight®, Edwards Lifescience, Irvine, CA) by an inflatable finger cuff placed on the midphalanx of hand middle or ring finger with no radial artery catheter and its heart reference system (HRS) is zeroed at the level of the patient's midaxillary line.~The ClearSight® monitoring is started in the pre-anaesthesia room and calibrated for 5 minutes before recording. The monitoring continues throughout the procedure until patient transfer in the recovery room. All data are anonymously collected on a USB pen for statistical analysis.
Study: NCT02306512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: H&E
Description: Sample will be stained with H\&E according to standard procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IHC MART-1
Description: Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IF MART-1
Description: Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IF MART-1
Description: Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IF cocktail
Description: The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.
Study: NCT03231787

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Platelet function assay
Description: Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.~It will be used to measure platelet function after withdrawal of the antiplatelet agent.~If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours.
Study: NCT00234988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sibutramine hydochloride monohydrate
Description: 10 mg QD with the option to increase dose to 15 mg QD up until Week 4
Study: NCT05850169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative Dance Therapy
Description: After completion of the initial assessments, the intervention group received 3 sessions per week of creative dance training for 4 weeks (12 sessions), with each session lasting approximately 40 minutes. The creative dance training took place in a 40-square-metre mirrored hall with a tatami mat on the floor. The training was conducted individually for each child in the IG. Different children's songs were selected for each session in harmony with the rhythm of the dance movements. In each session, 10 minutes of warm-up movements and 20 minutes of creative dance training were conducted, accompanied by songs. Meanwhile, materials such as spiky and heavy balls, ribbons, rhythm sticks and holihop were included in the application.~The creative dance training was planned by diversifying the 8 movement models (breath, tactile, core-distal, head-tail, upper-lower, body side, cross lateral and vestibular) of Brain Dance, which is a part of creative dance (Gilbert, 2002,2015).
Study: NCT04589676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naloxone training
Description: The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone training
Description: The naloxone training will teach participants about how to appropriately use naloxone in the event of an opioid overdose.
Study: NCT01304004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Satiety
Description: Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:~1. Experimental drinkable yogurt enriched in proteins and fibres~2. Placebo drinkable yogurt (isocaloric and isovolumetric)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Satiety
Description: Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:~1. Experimental drinkable yogurt enriched in proteins and fibres~2. Placebo drinkable yogurt (isocaloric and isovolumetric)
Study: NCT03394586

Intervention type: DRUG
Intervention: Exposure to golimumab
Description: retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
Study: NCT01814501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV
Study: NCT01514461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCQ908
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Study: NCT02245087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20 mg of atorvastatin daily
Study: NCT01200069

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen intravenous
Description: IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
Study: NCT00004932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT01609504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ELRR BY TEM
Description: The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LTME
Description: LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
Study: NCT01618825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Tablets 25 mg
Description: 2 x 25 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: 2 x 25 mg tablet once a day
Study: NCT04054531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study: NCT01578577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHMI
Description: The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
Study: NCT03672136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Chemoradiotherapy
Description: Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients
Study: NCT01524120

Intervention type: DEVICE
Intervention: Endoscopy (EPK-i, Pentax, Tokyo, Japan)
Description: Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.

Intervention type: DEVICE
Intervention: Endomicroscopy (iCLE, Pentax, Tokyo, Japan)
Description: Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
Study: NCT04054856

Intervention type: DEVICE
Group type: OTHER
Intervention: Body Sensor Network
Description: The Integrated Posture and Activity NEtwork by Medit Aachen (IPANEMA) Body Sensor Network (BSN) is a wireless sensor network with several sensor nodes. A sensor node consists of a base unit equipped with different sensor modalities: Acceleration sensor, Rotation rate sensor, Air pressure sensor, Photoplethysmography (PPG, optional), Galvanic Skin Response (GSR, optional) measurement. The sensor data is transmitted via a wireless 433/868 MHz ISM band radio link to the central radio node. From there, the data is transferred via a Bluetooth connection to a laptop or PC for processing. Three sensors are attached 1) to the wrist with a flexible Velcro strap, 2) hung around the neck on a specially designed collar and 3) worn loosely in the trouser pocket without further fixation or at the belt. The respective sensors are located in a closed, ergonomically shaped housing (size 70x40x20mm\^3, approx. 35g) and have no electrically conductive contact to the skin surface of the test person.

Intervention type: DEVICE
Group type: OTHER
Intervention: Body Sensor Network
Description: The Integrated Posture and Activity NEtwork by Medit Aachen (IPANEMA) Body Sensor Network (BSN) is a wireless sensor network with several sensor nodes. A sensor node consists of a base unit equipped with different sensor modalities: Acceleration sensor, Rotation rate sensor, Air pressure sensor, Photoplethysmography (PPG, optional), Galvanic Skin Response (GSR, optional) measurement. The sensor data is transmitted via a wireless 433/868 MHz ISM band radio link to the central radio node. From there, the data is transferred via a Bluetooth connection to a laptop or PC for processing. Three sensors are attached 1) to the wrist with a flexible Velcro strap, 2) hung around the neck on a specially designed collar and 3) worn loosely in the trouser pocket without further fixation or at the belt. The respective sensors are located in a closed, ergonomically shaped housing (size 70x40x20mm\^3, approx. 35g) and have no electrically conductive contact to the skin surface of the test person.
Study: NCT00992849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
Study: NCT00988845

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol
Description: 200 mg bid po X 8 weeks
Study: NCT01578577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Educator + EHMI
Description: This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.